Observational Study
Copyright ©The Author(s) 2018.
World J Gastroenterol. Oct 14, 2018; 24(38): 4403-4411
Published online Oct 14, 2018. doi: 10.3748/wjg.v24.i38.4403
Table 2 Characteristics of hepatitis C virus patients at waiting list registration before and after direct-acting antiviral introduction, according to indication to waiting list registration (decompensated liver disease or hepatocellular carcinoma)
dec-HCV
HCV/HCC
Pre-DAA n = 181 (%)Post-DAA n = 70 (%)P valuePre-DAA n = 144 (%)Post-DAA n = 94 (%)P value
Gender (male)139 (77)53 (75.7)ns118 (82)82 (87)ns
Age (yr)55 ± 855 ± 9ns57 ± 759 ± 60.03
BMI25 ± 325 ± 4ns24.7 ± 325 ± 3.6ns
Refractory ascites (yes)74 (40)32 (45.7)ns--
Blood groupnsns
086 (47.8)32 (45.7)62 (43)35 (39)
A70 (38.4)25 (35.7)52 (36)42 (44)
AB4 (2.2)4 (5.7)6 (4)5 (5)
B21 (11.5)9 (12.8)24 (17)12 (12)
HCC (yes)41 (22.5)24 (34.2)ns--
Comorbiditiesnsns
None134 (74.1)44 (62.8)104 (72.2)76 (80)
HBV7 (3.8)2 (2.8)8 (5.5)3 (3.2)
Alcohol34 (18.6)19 (27.1)26 (18)10 (10.6)
Metabolic6 (3.2)5 (7.3)6 (4.3)5 (5.3)
Child-Pugh classesns0.01
A6 (3.3)3 (4.2)64 (44.5)64 (68)
B67 (37)25 (35.7)67 (46.5)26 (27)
C108 (59.6)42 (60)13 (9)4 (4)
MELD score18.7 ± 619.3 ± 6ns11 ± 3.511 ± 3.4ns
HCV Genotype1nsns
1a18 (15.1)14 (23)11 (10.2)16 (18.8)
1b68 (57.1)34 (55.7)67 (62)39 (45.8)
212 (10)3 (4.9)10 (9.3)4 (4.7)
316 (13.4)6 (9.8)15 (13.9)22 (25.8)
45 (3.3)4 (6.5)5 (4.6)4 (4.7)
SVR achievement
None159 (87.8)39 (55.7)128 (89)45 (47.8)
Before WL registration13 (7.1)17 (24.2)0.00410 (7)24 (25.5)0.001
IFN based13 (7.1)2 (2.8)10 (7)6 (6.3)
During WL registration9 (4.9)14 (20)0.0096 (4)25 (26.5)0.001